No trading-relevant catalyst — this is a routine industry conference appearance with no disclosure of data, deals, or financing. Monitor for any subsequent press releases or 8-Ks from the BIO conference (June 22-25) that may contain material updates; absent those, the stock is likely to remain driven by cash-runway and development timeline news.
Price Chart
Executive Summary
Silexion Therapeutics, a clinical-stage biotech micro-cap ($2M market cap) developing RNAi therapies for KRAS-driven cancers, announced that management will attend the 2026 BIO International Convention (June 22-25, San Diego). This is a routine conference participation — no clinical data, regulatory decision, or financing was disclosed.
Key Facts
- Management attending BIO 2026 convention June 22-25 in San Diego
- CEO Ilan Hadar and CFO Mirit Horenshtein-Hadar named as attendees
- Company is clinical-stage, pre-revenue, focused on KRAS-driven cancers
- Market capitalization approximately $2M
- No clinical data, regulatory filing, financing, or partnership news released
Financial Impact
Not specified
Risk Factors
- No material news — conference attendance is standard and typically does not move stocks
- Micro-cap ($2M market cap) can be highly volatile on low volume regardless of fundamentals
- Company is pre-revenue and depends on financing to continue operations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3313043 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | DEFA14A | $0.1538 | awaiting T+20 | — | $0.1890 (−22.89%) |
Oct 5, 2026 21d ago | DEF 14A | $0.2628 | awaiting T+20 | — | $0.1890 (+28.08%) |
Sep 30, 2026 26d ago | 8-K | $0.2770 | awaiting T+20 | — | $0.1890 (−31.77%) |
Sep 30, 2026 26d ago | Press Release | $0.2773 | awaiting T+20 | — | $0.1890 (+31.84%) |
Sep 29, 2026 27d ago | 8-K | $0.3180 | awaiting T+20 | — | $0.1890 (+40.57%) |
Sep 29, 2026 27d ago | Press Release | $0.3184 | awaiting T+20 | — | $0.1890 (+40.64%) |
Sep 28, 2026 28d ago | 8-K | $0.2484 $0.1746 | ▼ −29.71% | ▼ −29.68% | $0.1890 (−23.91%) |
Sep 28, 2026 28d ago | Press Release | $0.2484 $0.1746 | ▼ −29.71% | ▼ −29.68% | $0.1890 (−23.91%) |
Sep 25, 2026 4w ago | 8-K | $0.2484 $0.1746 | ▲ +29.71% | ▲ +29.68% | $0.1890 (+23.91%) |
Aug 14, 2026 10w ago | 8-K | $0.4202 $0.3854 | ▲ +8.28% | ▲ +6.29% | $0.1890 (+55.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers